Triangle Global Health Consortium Recognizes Chimerix with 2015 Corporate Impact Award
February 8, 2015 - The Triangle Global Health Consortium is pleased to recognize Chimerix, Inc. as the winner of our 2015 Corporate Impact Award, Chimerix, Inc. Chimerix is a biopharmaceutical company dedicated to preventing and treating life-threatening infections. Chimerix was chosen for their work in developing oral antivirals to prevent disease in individuals with weakened immune systems and to treat viral diseases where no treatment is available. The award will recognize the efforts of Chimerix over the last decade to advance the clinical program of their lead candidate, brincidofovir. Originally developed to treat smallpox, brincidofovir is also being studied to prevent or treat common viruses -- such as cytomegalovirus (CMV) and adenovirus -- that can be deadly in people with weakened immune systems, especially following a stem cell (bone marrow) or organ transplant.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.